Current therapeutic strategies for non-small-cell lung cancer (NSCLC) treatment frequently employ pharmacological inhibitors to suppress oncogenic signaling induced by receptor tyrosine kinases (RTKs), including EGFR family members. However, this approach is eventually rendered ineffective in the majority of cases, due to selective emergence of drug resistance via receptor mutation and amplification. Deubiquitinating enzymes (DUBs) mediate the de-conjugation of proteins that would otherwise be tagged for degradation. We show that both silencing and pharmacological inhibition of USP8 (a DUB relevant to RTKs) leads to dramatic downregulation of EGFR, ERBB2, ERBB3 and including EGFR, ERBB2, ERBB3, and MET. We also determined that a synthetic USP8 inhibitor markedly decreased the viability of gefitinib-resistant and -sensitive NSCLC cells by decreasing RTK expression, while having no effect on normal cells. Moreover, treatment with a USP8 inhibitor led to significant reductions in tumor size in a mouse xenograft model using gefitinib-resistant and -sensitive NSCLC cells.
Introduction
Lung cancer remains the leading cause of cancer deaths worldwide. Non-small cell lung cancer (NSCLC) is the most common form and accounts for 85% of all cases (1) . Pharmacological inhibitors, including gefitinib and erlotinib, of the epidermal growth factor receptor (EGFR), have shown notable therapeutic effects in patients with specific forms of NSCLC (2) (3) (4) . However, despite a positive initial response to EGFR tyrosine kinase inhibitors (TKIs), many patients develop resistance to the drugs after varying periods of time (5) . Reports suggest that in approximately 70% of cases, resistance arises from a secondary mutation (T790M) in the EGFR and/or amplification of the MET gene (6, 7) . Therefore, novel treatment strategies to suppress the effects of changes in EGFR and MET are needed to successfully overcome gefitinib-and erlotinib-resistance in lung cancer therapy.
Various new approaches have been proposed to overcome EGFR-TKI resistance in lung cancer. Some recently developed novel inhibitors can attenuate the activity of EGFR even with a secondary T790M mutation (8) (9) (10) . Amplification of MET accounts for 25% of gefitinib-resistance cases in NSCLC (6) . A combination treatment with MET and EGFR inhibitors has also been examined as a means of enhancing the treatment outcome (11) (12) (13) . Additionally, the inhibition of related or downstream signaling pathways of EGFR and MET has also met with some success (14) (15) (16) .
Deubiquitinating enzymes (DUBs) primarily belong to the cysteine protease family and mediate the de-conjugation of ubiquitin-tagged substrates (17) . Ubiquitin-specific proteases (USPs) are a subclass of DUBs with specific targets of therapeutic importance (18) . Due to their highly-specific activity and involvement in several human pathologies including cancer, USPs are rapidly emerging as promising targets for drug design (19, 20) . USP8 (UBPy) was originally reported to be involved in cell growth with expression increasing upon induction by serum (21) . More recently, various interesting substrates of USP8 have been identified, including Nrdp1 (22) , ERBB2 (23) , and EGFR (24) (25) (26) .
Because USP8 is involved in EGFR degradation, we hypothesized that it might be an effective target for the treatment of NSCLC. In the present study, we determined that siRNA-knockdown of USP8 as well as inhibition with a synthetic small molecule inhibitor down-regulates USP8 activity, thereby leading to suppression of cell growth in gefitinib-resistant and -sensitive NSCLC cells through the attenuation of multiple RTKs.
Unlike approaches based on direct receptor-inhibitor concepts, we have shown that manipulation of USP8, an endogenous regulator of such receptors, can cause degradation of these proteins and thereby reduce the likelihood of further resistance emerging through receptor mutation or amplification. Our data suggest that USP8 is a promising drug target for gefitinib-resistant lung cancers.
Materials and Methods

Materials
Fetal bovine serum (FBS), and antibodies against USP8 and β-actin were purchased from Sigma-Aldrich (St Louis, MO). Gefitinib and erlotinib were purchased from LC Laboratories (Woburn, MA). Antibodies to detect phosphorylated ERBB3, ERBB2, EGFR, STAT3 and MET and total ERBB3, MET, STAT3 and Akt were purchased from Cell Signaling Technology (Beverly, MA). ERBB2, EGFR, ERK, and phosphorylated ERK antibodies were purchased from Santa Cruz (Santa Cruz, CA). The antibody for 
Cell viability assay
Cells were seeded in 96-well plates (1,000-3,000 cells per well depending on the cell type) and incubated overnight before treatment. Cell viability was measured using the 
Immunoblotting
After cells were seeded in a 100-or 60-mm dish overnight, the indicated chemicals or siRNA were administered for the times indicated. Harvested cells were disrupted with cell lysis buffer (Pierce, Rockford, IL) and the proteins were collected. The protein concentration was determined using a dye-binding protein assay kit (Bio-Rad) as described in the manufacturer's manual. Protein lysate (20-80 μg) was subjected to SDSpolyacrylamide gel electrophoresis and electrophoretically transferred to a polyvinylidene difluoride membrane. After blotting, the membrane was incubated with a specific primary antibody at 4°C overnight. Protein bands were visualized by a chemiluminescence detection kit after hybridization with an AP-linked secondary antibody.
RNA interference
Cells were grown in 60-or 100-mm dishes and transfected with either a USP8-specific 
RTK array
To analyze phospho-RTK profiles, we used the Human Phospho-RTK array kit (R&D Systems, Minneapolis, MN). Cells were lysed with Pierce IP lysis buffer (Thermo Scientific, Waltham, MA). Protein concentration were quantified and applied as described in the manufacturer's protocol. After applying chemiluminescence detection solution, the blots were imaged using a ChemiDoc XRS+ System (Bio-Rad). Cover slips were fixed and cells were imaged immediately with a Zeiss LSM700 confocal scanning microscope equipped with a Zeiss T-PMT digital camera (Zeiss, Oberkochen,
Immunofluorescence microscopy
Germany). Negative control normal IgGs were used to confirm the reliability of signal localization. For animal tissue analysis, citrate buffer antigen retrieval was used. Primary antibodies were diluted at 1:250. The other steps were same as described above.
Apoptosis analysis
Cells were plated in 60-mm plates and treated or not treated with siRNA or USP8 inhibitor for 48 hours. Cells were fixed in 70% ethanol and stored at −20°C for 24 hours.
After staining with Annexin V, apoptosis was determined using a BD FACSCalibur Flow Cytometer (BD Biosciences).
Semi-quantitative RT-PCR
Total RNA was extracted from cultured cells using TRIzol reagent (Tel-Test, Inc., 
Deubiquitinating enzyme assay
The activity of USP8 was measured by DUB-Glo™ Protease Assay (Promega). The USP8 protein was purchased from Abcam (Cambridge, UK). The indicated concentrations of USP8 inhibitor were added to the reaction mixture.
Results
Knock-down of USP8 selectively decreases viability of gefitinib-resistant NSCLC cells. To investigate the effects of USP8 knockdown on viability of gefitinib-resistant NSCLC cells, we transfected siRNAs targeting USP8 (si-USP8) or a scrambled mock control (si-control) into two gefitinib-resistant NSCLC cell lines (i.e., H1975 and H1650). 
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USP8 showed a dramatic decrease in cell viability compared to mock-transfected cells, indicating that the suppression of USP8 effectively decreases NSCLC cell viability ( Fig.   1A and Supplementary Fig. 1C ). In contrast, knockdown of USP8 in normal human bronchial epithelial cells, human lung fibroblasts, and primary dermal fibroblasts had no effect on viability (Fig. 1B and Supplementary Fig. 1A, C) . Effective knockdown of USP8 was confirmed by Western blotting (Fig. 1C) . Gefitinib and erlotinib did not show significant effects on viability of NSCLCs or normal cells (Fig. 1A, B) . Also, knockdown of USP8 led to induction of apoptosis in NSCLC cells but not in normal bronchial epithelial cells (Supplementary Fig. 2C ).
Knockdown of USP8 inhibits the expression of multiple RTKs in gefitinib-resistant
NSCLC cells. Because USP8 was reported to regulate RTKs including EGFR and ERBB2 (23, 25), we explored this relationship using an RTK array to compare the effect of USP8 knockdown on 42 human RTKs in H1975 and H1650 cells. Phosphorylated forms of EGFR, ERBB2, ERBB3, and MET were markedly reduced upon USP8 knockdown compared to mock-transfected cells (Fig. 2A) . Western blotting confirmed that knockdown of USP8 not only reduced RTK phosphorylation, but also the total levels of EGFR, ERBB2, ERBB3, and MET in H1975 and H1650 cells (Fig. 2B) . The mRNA levels of EGFR, ERBB2, ERBB3, and MET did not change (Supplementary Fig. 3) . 3A ) (27) , effectively attenuated the deubiquitinating activity of USP8 in vitro (Fig 3B) .
We next tested the effect of USP8 inhibition on cell viability using multiple cell lines, including the gefitinib-resistant NSCLC cell lines H1975, H1650, and HCC827GR, as well as the gefitinib-sensitive NSCLC cell line HCC827. The normal bronchial epithelial cell HBTEC and NL20 and lung fibroblast cell lines CCD8-Lu and WI-38 were also subjected to USP8 inhibitor treatment as controls representing non-cancerous cells. USP8 inhibition markedly reduced cell viability in gefitinib-resistant and -sensitive NSCLC cells, but exhibited no observable effects on normal control cells (Fig. 3C) . Treatment of the USP8 inhibitor induced apoptosis in NSCLC cells but not in bronchial epithelial cells ( Supplementary Fig. 4) . In order to better understand the mechanism of selective killing of NSCLCs, we analyzed the endogenous expression levels of USP8, EGFR, ERBB2, ERBB3, and MET and found that their expression levels were substantially increased in NSCLC cells relative to normal cells (Fig 3D) .
A USP8 inhibitor reduces RTK expression and downstream signaling in NSCLC cells.
We examined the effect of the USP8 inhibitor or gefitinib on RTK levels and downstream signaling in NSCLC cells. Gefitinib-resistant H1975, H1650, and HCC827GR cells as well as gefitinib-sensitive HCC827 cells were exposed to 1 μM USP8 inhibitor or gefitinib. USP8 inhibitor treatment led to the suppression of phosphorylated and total EGFR, ERBB2, ERBB3, and MET in gefitinib-resistant andsensitive NSCLC cells (Fig. 4A-D 4A-D) . The USP8 inhibitor substantially suppressed the phosphorylation of STAT3, Akt, and ERKs, which are downstream targets of RTKs in gefitinib-resistant and -sensitive NSCLC cells (Fig. 4A-D) . In contrast, gefitinib treatment inhibited phosphorylation of STAT3, Akt, and ERKs in gefitinib-sensitive HCC827 cells (Fig. 4D) , but not in gefitinib-resistant NSCLC cells (Fig. 4A-C) .
Inhibition of USP8 enhances co-localization between ubiquitin and target RTKs.
Because treatment with the USP8 inhibitor reduced RTK expression, and USP8 has been reported to deubiquitinate target proteins (23, 25) , we investigated the possible role of the USP8 inhibitor in modulating ubiquitination of RTKs. We analyzed ubiquitin localization in relation to EGFR and ERBB2 (i.e., as representative RTKs) after USP8 inhibitor treatment and found that treatment increased co-localization between ubiquitin and both EGFR (Fig. 5A) and ErbB2 (Fig. 5B) . We used fluorescence intensity scanning to confirm that co-localizing ubiquitin and EGFR/ERBB2 fluorescent signals were more spatially distinct in control treatments than with the USP8 inhibitor ( Supplementary Fig.   5 ). (Fig. 6A, B) .
Inhibition of NSCLC tumor growth in a xenograft
Although gefitinib prevented tumor growth in HCC827 xenografts more effectively than the USP8 inhibitor alone (Fig. 6C) , it was less effective in gefitinib-resistant H1975 and HCC827GR tumors compared to the same dose of USP8 inhibitor (Fig. 6A, B) . To confirm that inhibition of USP8 prevented RTK activation in vivo, we assessed the expression of phosphorylated EGFR, ERBB3, and c-MET in the recovered xenograft tumors. Consistent with our Western blot data for USP8 inhibitor-treated NSCLC cells, phosphorylated EGFR, ERBB3, and c-MET were markedly down-regulated in the presence of the USP8 inhibitor in tumor tissues (Fig. 6D) .
Discussion
EGFR-TKIs including gefitinib and erlotinib, have a long established reputation for therapeutic efficacy in NSCLC patients (2, 3, 28) . However, despite initial positive responses to these inhibitors, sustained regression of the disease is invariably hampered by the emergence of drug resistance. Identified mechanisms of resistance include gatekeeper mutations in EGFR and the activation of bypass survival signals mediated through the MET and ERBB3 receptors (6, 7) . To overcome acquired resistance to EGFR-TKIs, conventional approaches have focused on suppressing the activity of mutant-EGFR, MET or related signaling molecules through novel inhibitors that can bind the mutant receptor conformations (6, 9, 15, 16) . However, such approaches are prone to the possibility of selection for further receptor mutations that bring renewed drug resistance or require multiple drug treatments (29, 30) . We propose that selective downregulation of the total levels of oncogenic RTKs including EGFR and MET, by 
manipulating a specific mechanism of endogenous protein regulation could provide more effective control over NSCLCs with or without EGFR-TKI resistance. Here we observed that knockdown of USP8 levels by siRNA or inhibition by a small-molecule inhibitor effectively decreased the viability of gefitinib-resistant NSCLCs.
Regulation of the ubiquitin conjugation/de-conjugation system to generate more specific, less toxic anticancer agents has recently emerged as a promising therapeutic strategy (19, 20, 31) . DUBs act at various points in the ubiquitin pathway removing ubiquitin from substrates to change the fate of proteins (32) . Recent studies have revealed that various oncogene products and tumor suppressors are regulated by DUBs (33-37), which has led to the idea that their targeted inhibition or activation could enhance cancer therapies. Our data suggest that USP8 is a promising new drug target for lung cancer through its influence on multiple oncogenic RTKs.
Members of the EGFR family, including EGFR, ERBB2, ERBB3, and ERBB4 and MET, are heavily involved in various signaling pathways that promote the proliferation, survival, angiogenesis, and metastasis of cancer cells (38, 39) . Activating mutations or overexpression of these RTKs can be frequently observed in a wide range of cancers, and their identification typically results in a poor prognosis (40) (41) (42) . Given the medical importance of EGFR function in cancer, several small-molecule inhibitors and antibodies have been developed that inhibit EGFR and ERBB2 activity (39) . Similarly, MET stimulates proliferation, cell scattering, invasion, and protection from apoptosis and has been reported to exist in human tumors with activating mutations, gene amplification, and underway with agents including small-molecule inhibitors and antibodies targeting these receptors to determine if these concepts can translate into therapeutic application (43) .
RTKs such as EGFR, ERBB2, ERBB3, and MET have been reported to crosstalk with each other, and one RTK can drive the activity of others (38, 45) . The signaling connections between these RTKs, particularly EGFR and MET, has been identified as a cause of EGFR-TKI resistance, necessitating multiple RTK suppression to achieve adequate therapeutic outcomes (6, 29, 46) . Because EGFR and ERBB2 have been identified as targets of USP8-related deubiquitination, we sought to determine whether modulation of USP8 activity could influence endogenous levels of these proteins. We report that USP8 suppression, by either siRNA or synthetic inhibitor, leads to the multiple oncogenic RTK down-regulation of EGFR, ERBB2, ERBB3, and MET while simultaneously inducing significant anticancer effects in both gefitinib-resistant andsensitive NSCLC cells.
Interestingly the siRNA-mediated knockdown and pharmacological inhibition of USP8 showed strong selectivity toward suppression of NSCLC growth, but had minimal effects on normal cells. We have also determined that basal expression levels of USP8 and its targets, EGFR, ERBB2 ERBB3, and MET, are elevated in lung cancer cells compared to normal cells. These findings provide insight as to why the suppression of USP8 could be specific for cancer cells while leaving normal cells unharmed, because many cancers including NSCLCs are addicted to RTK signaling pathways for their survival (38, 46) . For this reason, many recent targeted cancer therapies have focused on generating new drugs that specifically target proteins malfunctioning in tumors, to achieve more effective and less toxic outcomes (47). Treatment with the USP8 inhibitor was more effective in suppressing gefitinib-resistant NSCLC cell growth than that of sensitive lines. Although gefitinib-resistant HCC827GR cells were generated from the gefitinib-sensitive HCC827 cells (6) , and thus share the same genetic background, they were more sensitive to USP8 inhibitor treatment. Because the HCC827GR line has been reported to exhibit a high dependency toward MET and EGFR, suggesting that the more dependent a cell becomes to USP8 targets like EGFR, ERBB2, ERBB3, and MET, the higher the sensitivity could become towards USP8 inhibition is not unreasonable. Our phospho-RTK array data using H1975 and H1650 gefitinib-resistant cell lines revealed that the strongest phosphorylation of RTKs were EGFR, ERBB2, ERBB3, and MET, adding further weight to the idea that these RTKs provide pro-survival mechanisms for these cell lines. Interestingly, while USP8 inhibition and knockdown reduced levels of the phosphorylated insulin receptor, it had no effect on total levels of the protein (Supplementary Fig. 6 ). This supports the idea that USP8 specifically regulates target substrates as opposed to having broad effects on multiple RTKs. Notably, the RTK status of a given tumor type might be an important factor when selecting tumors for USP8 therapeutic targeting.
Taken together, our findings demonstrate for the first time that inhibition of USP8 down-regulates the total protein levels of EGFR, ERBB2, ERBB3, and MET, and effectively attenuates related RTK signaling pathways. These observations provide proofof-principle that targeting USP8 can selectively kill cancer cells without adverse effects on normal cells. More specifically, our data suggest that inhibition of USP8 is an effective method for overcoming gefitinib-resistance in non-small cell lung cancer. 
